Pharma R&D Annual Review 2023 Supplement: New Active Substances Launched During 2022

By Ian Lloyd, Senior Director, Pharmaprojects at Citeline

In a sequel to the Pharma R&D Report, respondents were asked exclusively about new active substances (NASs): new chemical or biological entities where the active ingredient had received no prior approval for human use, in addition to vaccines with novel antigenic components. It excluded an additional 83 first drug launches of reformulated or non-NAS moieties, biosimilars, and imaging agents. Instead, the report focused on first editions of genuinely new drugs and molecules, continuing the literary theme of the Pharma R&D Report for the year, and leaving other reprints aside.

Specifically, the latest report highlights the challenges of getting drugs published, such as imitating existing therapies, side effects, and poor efficacy, just like in the writing industry, where only 1% to 2% of manuscripts get published. The article stresses the importance of innovation and advancement in patient care and celebrates the successful launch of genuinely new and innovative drugs.

Access this white paper and explore the drugs that brought something genuinely new to the world of medicine in 2022 that just might have the potential to change the story of patients’ lives.